Bone disease in eliglustat treated Gaucher disease type 1 patients: A real-world experience in a tertiary referral hospital

被引：0
|
作者：
Valls-Villalba, Angel [1 ]
Camprodon-Gomez, Maria [2 ]
Moreno-Martinez, Daniel [3 ]
Hernandez-Vara, Jorge [4 ]
Arranz-Amo, Jose Antonio [5 ]
Carnicer-Caceres, Clara [5 ]
机构：
[1] Vall Hebron Univ Hosp, Internal Med, Barcelona, Spain
[2] Vall DHebron Univ Hosp, Unit Rare Dis & Metab Hereditary Disorders, Barcelona, Spain
[3] Vall Hebron Univ Hosp, Dept Radiol, Barcelona, Spain
[4] Vall Hebron Univ Hosp, Dept Neurol, Unit Movement Disorders, Barcelona, Spain
[5] Vall Hebron Univ Hosp, Inborn Error Metab Lab, Barcelona, Spain
来源：
MOLECULAR GENETICS AND METABOLISM | 2023年 / 138卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2022.107340
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
357
引用
收藏
页码：129 / 129
页数：1
相关论文
共 50 条
  • [31] Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project
    Giraldo, Pilar
    Alfonso, Pilar
    Atutxa, Koldo
    Fernandez-Galan, Maria A.
    Barez, Abelardo
    Franco, Rafael
    Alonso, Dora
    Martin, Alejandro
    Latre, Paz
    Pocovi, Miguel
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (12): : 1771 - 1775
  • [32] Type 1 Gaucher disease (CYP2D6-eliglustat)
    Becquemont, Laurent
    THERAPIE, 2017, 72 (02): : 323 - 326
  • [33] Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy
    Zimran, Ari
    Goldblatt, Jack
    Szer, Jeff
    BLOOD CELLS MOLECULES AND DISEASES, 2018, 68 : 14 - 16
  • [34] Real-World Experience of Ustekinumab in Crohn's Disease Patients With Prior Anti-TNF Therapy at a Tertiary Care Hospital
    Kartikeya, Tripathi
    Kevin, Groudan
    Jean, Chalhoub
    Arushika, Yedla
    Rohit, Singhania
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S17 - S17
  • [35] CLINICAL OUTCOMES OF USTEKINUMAB IN RESISTANT CROHN'S DISEASE: UK IBD TERTIARY REFERRAL CENTRE 'REAL-WORLD' EXPERIENCE
    Borg-Bartolo, Simon Peter
    Kemp, Karen
    Willert, Robert P.
    Makin, Alistair J.
    Levison, Scott Edward
    GUT, 2018, 67 : A71 - A72
  • [36] Bone marker alterations in patients with type 1 Gaucher disease
    Ciana, G
    Martini, C
    Leopaldi, A
    Tamaro, G
    Katouzian, F
    Ronfani, L
    Bembi, B
    CALCIFIED TISSUE INTERNATIONAL, 2003, 72 (03) : 185 - 189
  • [37] Real-world effectiveness of eliglustat in treatment-naive and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
    Mistry, Pramod K.
    Balwani, Manisha
    Charrow, Joel
    Kishnani, Priya
    Niederau, Claus
    Underhill, Lisa H.
    McClain, Monica R.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (09) : 1038 - 1046
  • [38] Bone turnover markers in patients with type 1 Gaucher disease
    Giuffrida, Gaetano
    Cingari, Maria Rocca
    Parrinello, Nunziatina
    Romano, Alessandra
    Triolo, Anna
    Franceschino, Magda
    Di Raimondo, Francesco
    HEMATOLOGY REPORTS, 2012, 4 (04) : 70 - 79
  • [39] Bone Marker Alterations in Patients with Type 1 Gaucher Disease
    G. Ciana
    C. Martini
    A. Leopaldi
    G. Tamaro
    F. Katouzian
    L. Ronfani
    B. Bembi
    Calcified Tissue International, 2003, 72 : 185 - 189
  • [40] The clinical efficacy of imiglucerase versus eliglustat in patients with Gaucher's disease Type 1: A systematic review
    Nabizadeh, Azita
    Amani, Bahman
    Kadivar, Maliheh
    Toroski, Mahdi
    Asl, Akbar Abdollahi
    Bayazidi, Yahya
    Mojahedian, Mahdi
    Davari, Majid
    JOURNAL OF RESEARCH IN PHARMACY PRACTICE, 2018, 7 (04) : 171 - 177
12345